Doug Drysdale

Cybin Inc. (NYSE: CYBN) announced that it has received approval from an independent ethics committee in the Netherlands to begin the first in-human dosing of its proprietary deuterated N, N-dimethyltryptamine (DMT) molecule CYB004 through a protocol amendment to its ongoing CYB004-E...

Cybin Inc. (NEO: CYBN) (NYSE AMERICAN: CYBN), a biopharmaceutical company focused on psychedelics for mental health, announced Tuesday that the first two participants have been dosed in its Phase 1/2a trial evaluating CYB003 for the treatment of the major depressive disorder (MDD). CYB003 is...

Cybin Inc. (NEO: CYBN) (NYSE: CYBN) and Clinilabs Drug Development Corporation (Clinilabs) announced that the U.S. Drug Enforcement Agency (DEA) has granted a Schedule I license to support the first-in-human Phase 1/2a clinical trial of CYB003, a proprietary deuterated psilocybin analog being...

Three weeks after announcing the results of its preclinical trials for CYB003, Cybin (NYSE:CYBN) made public a partnership with Clinilabs Drug Development Corporation to take the proprietary drug to its next phase. Clinilabs is to carry out Cybin’s Phase 1/2a clinical trial of CYB003 for...

If you’re just now considering the therapeutic value of psychedelics, Cybin Inc (NYSE: CYBN) is many trips ahead of you. The Toronto-based company is studying derivatives of psilocybin and DMT and plans to file an investigational new drug application with the FDA during this quarter, CEO Doug...

From his beginnings at DuPont Merck to his current position as Cybin’s (NYSE: CYBN) CEO, Doug Drysdale has certainly had an eventful career. “I seem to be drawn to opportunities that are poised for growth, whether that is from being undermanaged, distressed or a startup situation,...

Cybin Inc (NASDAQ: CYBN) shares are trading higher after the company announced an Institutional Review Board granted approval for a Cybin-sponsored feasibility study using Kernel Flow technology to measure psychedelic effects on the brain. “By leveraging the Kernel Flow technology, we may...

Toronto-based, Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics,” reported its unaudited financial results on Monday for the second quarter ended September 30, 2021. Second-Quarter Financial Highlights Cash...

Cybin Inc (NYSE: CYBN), a Toronto-based biotechnology company focused on utilizing psychedelic drugs as an alternative to traditional psychiatric drugs, announced positive pre-clinical data, indicating that its drug, CYB003 showed strong signs of cognitive improvement in patients with Major...